Genmab banks $22M from J&J as myeloma drug ticks forward

Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson ($JNJ). J&J signed a deal worth up to $1.1 billion to get its hands on global rights to the drug, taking an $80 million equity stake in Genmab and handing over a $55 million upfront payment. Daratumumab is a CD38 antibody with potential in leukemia and lymphoma, and the drug picked up the FDA's coveted breakthrough therapy designation for multiple myeloma last year. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.